Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination

Abstract

Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy. © 2013 Landes Bioscience.